Business Wire

Mary Kay Inc. Joins Forces with the Equal Rights Trust to Pioneer Research on Gender Inequality in Algorithms and Artificial Intelligence

4.10.2021 11:00:00 EEST | Business Wire | Press release

Share

Mary Kay Inc., a global leader in women’s empowerment, today announced a partnership with the Equal Rights Trust (ERT), an organization whose mission is to eliminate all forms of discrimination and ensure everyone can participate in society on an equal basis. Established in 2007, the Trust works in partnership to advance equality through law around the world. As part of this collaboration, Mary Kay Inc. will help ERT jumpstart an innovative field of research on artificial intelligence and algorithms through a gender-based lens.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005308/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Equal Rights Trust logo (Graphic: Mary Kay Inc.)

“As a company founded on the mission to enrich the lives of women everywhere, Mary Kay is constantly on the lookout for organizations we can partner with to make an impact for gender equality globally,” said Julia Simon, Chief Legal Officer and Chief Diversity Officer of Mary Kay Inc. “We’re excited to support Equal Rights Trust on their work to help advance equality by design and beyond forge a way forward to collaborations with the private sector. Our work with ERT is specifically focused on framing the new landscape of artificial intelligence and gender equality, a growing concern in the digital age.”

Mary Kay’s support to the ERT will pioneer a new field of research on the discriminatory impact of algorithmic systems. ERT has developed and promoted models of equality impact assessment, advocating an “equality by design” approach in public and private decision making as a means to ensure non-discrimination and equality of participation. An immediate priority is to launch an initiative to establish and address the emerging discriminatory impacts of algorithmic decision-making, specifically as it relates to gender.

“The use of algorithms and artificial intelligence is spreading,” said Ariane Adam, Deputy Director of the Equal Rights Trust. “These technologies are rapidly becoming essential parts of the analytical, communication, and even legal infrastructure for our societies. Despite the global proliferation of such systems, we are only just beginning to understand the flaws, limitations, and boundaries of algorithmic decision making, especially in terms of discrimination. We’re pleased to partner with Mary Kay to shine light on the potentially discriminatory impacts of using such technologies, in particular for women.”

The delivery of the initiative can be broken into three phases:

  • Phase 1: research on emerging discriminatory impacts of the use of algorithmic-decision making in the areas of employment, access to loans, and access to housing, including a focus on the impact of women as a group particularly exposed to discrimination in these contexts.
  • Phase 2: engagement with a wide-range of actors to develop advocacy strategies to call for an equality by design approach in the design, development, roll-out and monitoring of AI technologies.
  • Phase 3: engaging with international, regional and national actors to set standards mandating an equality by design approach.

The partnership with the Equal Rights Trust is just the latest initiative supported by Mary Kay in 2021 to advocate for gender equality everywhere. For nearly 60 years, Mary Kay has been committed to empowering women and their families by partnering with organizations from around the world.

ABOUT EQUAL RIGHTS TRUST

The Equal Rights Trust is an independent international non-governmental organization which exists to eliminate discrimination and ensure everyone can participate in society on an equal basis. To achieve this mission, it works in partnership with equality defenders – civil society organizations (CSOs), lawyers, government representatives, and others committed to using law to create an equal world – providing them with the technical, strategic and practical support they need to work for the adoption and implementation of comprehensive equality laws. Since 2007, it has supported equality defenders in almost 50 countries, while developing consensus at the international level on the need for and content of comprehensive equality laws. Learn more at equalrightstrust.org

ABOUT MARY KAY

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company 58 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at marykayglobal.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 15:01:00 EEST | Press release

Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps, supplying inhibitors, biocides and PH control additives. Hyper scale datacenters require new type of cooling solutions. In today’s liquid-cooled data centers, coolant quality and water treatment is becoming a rising issue. Left unmanaged, chemistry drift quietly takes away cooling pe

STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 15:00:00 EEST | Press release

STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executing in “a structurally challenged print market.” Since our September letter, we’ve continued to actively engage with Xerox, including at the recent PRINTING United Expo in Las Vegas, and our conversations have been encouraging. We greatly appreciate the willin

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data include an oral proffered paper presentation on BeOne’s GPC3x4-1BB bispecific antibody, currently being studied in hepatocellular carcinoma (HCC) and first-in-human data for two investigational lung cancer assets, a CEA targeting antibody-drug conjugate (ADC), in CEA-expressing non-small cell lung cancer (NSCLC), and a brain-penetrant PRMT5 inhibitor in MTAP-deleted tumors, inclu

The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Experts in Vienna19.10.2026 13:00:00 EEST | Press release

Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent challenge: transforming Europe's data centre energy landscape. We brought together leaders from across the data ce

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO ® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 12:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically relevant target in the treatment of moderate to severe ulcerative colitis.1 Results were presented during late-breaker and poster sessions at United European Gastroenterology (UEG) Week 2026 and published in the United European Gastroenterology Journal. “There has been increasing conversation about whether achieving deeper levels of remission – addressing both visible and microscopic inflammation

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye